As healthcare professionals, our understanding of Parkinson's disease (PD) is crucial in providing effective patient care. PD is a progressive, neurodegenerative disorder that affects movement, muscle control, and balance.
PD primarily affects the dopamine-producing neurons in the substantia nigra, a region of the brain that controls movement. The exact cause is unknown, but both genetic and environmental factors are implicated. The characteristic motor symptoms are due to the loss of dopamine, resulting in an imbalance of excitatory and inhibitory signals in the basal ganglia.
PD typically presents with resting tremor, bradykinesia, rigidity, and postural instability. However, non-motor symptoms such as depression, cognitive impairment, and autonomic dysfunction often precede the motor symptoms and significantly affect the quality of life.
PD is primarily diagnosed clinically, based on the presence of cardinal motor symptoms and their response to dopaminergic therapy. Neuroimaging and genetic testing can support the diagnosis but are not routinely used due to their limited sensitivity and specificity.
While there is no cure for PD, the goal of treatment is to manage symptoms and improve quality of life. Pharmacological therapy, primarily with levodopa and dopamine agonists, is the mainstay of treatment. Non-pharmacological interventions, including physical therapy and lifestyle modifications, also play a crucial role.
Understanding Parkinson's disease is paramount for healthcare professionals. By recognizing the clinical features, understanding the pathophysiology, and being aware of the latest treatment strategies, we can ensure that our patients receive the best possible care. Continuous research and advancements in this field offer hope for better management strategies and, ultimately, a cure for this debilitating disease.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation